Skip to main content
. Author manuscript; available in PMC: 2019 Aug 29.
Published in final edited form as: Vaccine. 2016 May 7;34(27):3030–3036. doi: 10.1016/j.vaccine.2016.04.097

Fig. 2.

Fig. 2.

Potentially achievable vs. reported vaccination coverage and 95% confidence interval for the 4+DTaP*, 4+PCV†, Hib-FS§, by State in the United States, National Immunization Survey, 2013. * ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. † ≥4 doses of pneumococcal conjugate vaccine (PCV). § Full series Haemophilus influenzae type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus influenzae type b (Hib-FS) vaccine depending on product type received (includes primary series plus the booster dose).